Align Technology, Inc.

Align Technology, Inc. (ALGN) Market Cap

Align Technology, Inc. has a market capitalization of $13.61B.

Financials based on reported quarter end 2025-12-31

Price: $190.07

5.05 (2.73%)

Market Cap: 13.61B

NASDAQ · time unavailable

CEO: Joseph Hogan

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2001-01-30

Website: https://www.aligntech.com

Align Technology, Inc. (ALGN) - Company Information

Market Cap: 13.61B · Sector: Healthcare

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Analyst Sentiment

72%
Strong Buy

Based on 17 ratings

Analyst 1Y Forecast: $187.60

Average target (based on 6 sources)

Consensus Price Target

Low

$185

Median

$200

High

$220

Average

$204

Potential Upside: 7.2%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 Align Technology, Inc. (ALGN) — Investment Overview

🧩 Business Model Overview

Align Technology is a medtech innovator best known for its Invisalign system, which pioneered the segment of clear aligner orthodontics as an alternative to traditional braces. The company combines proprietary hardware with digital imaging, 3D modeling, and treatment planning software to offer comprehensive solutions for dental professionals and patients. Its core customer base includes orthodontists, general dental practitioners, and dental service organizations globally. By owning the full workflow—from intraoral scanning to treatment planning and aligner fabrication—Align operates across various geographies and serves a diverse patient demographic, spanning teenagers to adults seeking discreet orthodontic care.

💰 Revenue Model & Ecosystem

Align’s revenue model is multifaceted, capturing value across both hardware and software, as well as ongoing services. The flagship Invisalign aligner system generates recurring sales as each new patient requires a bespoke set of aligners, while ongoing case refinements provide additional revenue streams. The iTero family of intraoral scanners forms the backbone of its digital dental ecosystem, typically sold to practices as capital equipment with complementary software licenses, upgrades, and cloud-enabled workflow integration. Subscription-based digital services, such as treatment planning and monitoring, further support practitioners in delivering optimal patient outcomes, creating a tightly integrated, high-switching-cost environment. The company caters primarily to professionals, but enjoys indirect consumer brand recognition due to patient-facing marketing and demand pull.

🧠 Competitive Advantages

  • Brand strength: Invisalign has become synonymous with clear aligner treatment, supported by significant consumer outreach and professional trust.
  • Switching costs: Integrating Align’s ecosystem—including iTero scanners, proprietary software, and aligner logistics—creates friction for switching to competing solutions, especially at scale in multi-chair practices.
  • Ecosystem stickiness: Seamless integration across imaging, planning, manufacturing, and practice management tools encourages long-term practitioner loyalty and higher patient throughput.
  • Scale + supply chain leverage: Align’s global reach, advanced manufacturing capabilities, and sophisticated logistics underpin cost advantages and the ability to serve a large, fragmented dental market efficiently.

🚀 Growth Drivers Ahead

Align’s long-term growth is fueled by the secular penetration of clear aligner therapy in both developed and emerging markets, as growing orthodontic awareness and aesthetics drive demand from teens and adults. Expansion of its digital ecosystem—for example, through enhancements to intraoral scanning, artificial intelligence-driven treatment planning, and new clinical indications—opens additional addressable market segments. Partnerships with dental organizations, investments in practitioner training, and direct-to-consumer marketing continue to increase adoption and utilization rates. Furthermore, Align’s focus on product innovation and digital workflow integration positions it favorably as dentistry shifts towards more personalized, data-driven care.

⚠ Risk Factors to Monitor

Key risk areas include intensifying competition from both established dental device companies and new entrants in the aligner market, which could exert pricing and margin pressure. Regulatory changes and evolving standards in healthcare technology or dental practice protocols may require ongoing compliance investment and product adaptation. Disruption from technological advances, such as in-office 3D printing of aligners or new orthodontic modalities, may challenge Align’s value proposition if not met with timely innovation. Economic sensitivity in elective dental procedures can impact patient demand, while dependency on practitioner adoption highlights the importance of maintaining relationships and education initiatives in face of competitor incentives or shifting industry dynamics.

📊 Valuation Perspective

The market often assigns Align a premium valuation relative to the broader dental and healthcare technology sector, reflecting its leadership status, high brand affinity, and robust growth profile. Investors typically recognize the company’s scalable business model, sticky ecosystem, and substantial runway for global market penetration, balancing this against cyclical variability and ongoing investment needs. Relative valuation considerations also factor in Align’s capacity for innovation and execution in expanding its digital platform versus legacy device-centric peers.

🔍 Investment Takeaway

Align Technology represents a compelling growth play on orthodontic digitization and consumer-driven healthcare, underscored by powerful brand equity and an entrenched ecosystem. Optimists highlight secular tailwinds, a strong innovation pipeline, and wide competitive moats as drivers for sustained outperformance. Bears may point to rising competition, technological disruption threats, and margin risks as headwinds that could moderate long-term returns. Ultimately, Align’s investment profile hinges on its ability to continuously expand its platform and maintain relevance amidst evolving market and technological landscapes, balancing attractive growth prospects with sector-specific risks.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Align Technology reported a quarterly revenue of $1.05 billion, with an EPS of $1.89. The net margin for the quarter was 12.95%, and the company generated $188.72 million in free cash flow. Year-over-year growth was stable, indicating robust sales and consistent profit generation. The company maintains a strong balance sheet, with total assets of $6.23 billion, total liabilities of $2.18 billion, and total equity of $4.05 billion, resulting in net debt of -$1.01 billion, reflecting a solid cash position. Operating cash flow was $188.72 million, fully translating into free cash flow as there were no capital expenditures. The company returned substantial value to shareholders by repurchasing $297.13 million in stock during the quarter, though it did not pay out dividends. Analysts have set a consensus target price of $176.43, suggesting moderate confidence in the company's future performance. Align Technology's valuation and performance metrics indicate a stable financial position with efficient operations, although the absence of dividends may influence certain income-seeking investors."

Revenue Growth

Positive

Revenue reached $1.05 billion, showing stable growth driven by core orthodontic products.

Profitability

Good

Net margin at 12.95% and EPS at $1.89 reflect strong operational efficiency and profitability.

Cash Flow Quality

Strong

Strong free cash flow due to high operating cash flow and no capital expenditures; substantial buybacks.

Leverage & Balance Sheet

Strong

Negative net debt suggests strong liquidity and a robust financial position with high equity.

Shareholder Returns

Neutral

Significant stock repurchases enhance shareholder value, but no dividends limit returns for income investors.

Analyst Sentiment & Valuation

Neutral

Consensus price target of $176.43 indicates moderate upside, reflecting balanced analyst sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Align delivered a strong Q4 with record revenue and clear aligner volumes, non-GAAP gross margin expansion, and the highest non-GAAP operating margin since 2021. Growth was broad-based across EMEA, APAC, and Latin America, with DSOs driving adoption and North America stabilizing despite consumer softness. The company is advancing its digital ecosystem and transitioning to direct 3D printing with initial product releases planned in 2026. While FX, ASP pressure, North American retail softness, and potential China VPP pricing remain watch items, management’s tone was confident given operational execution, platform momentum, and DSO-led growth.

Growth

  • Record Q4 revenue $1.048B (+5.3% y/y, +5.2% q/q)
  • Q4 clear aligner revenue $838.1M (+5.5% y/y, +4.0% q/q) on record 677k cases (+7.7% y/y, +4.5% q/q)
  • Q4 Systems & Services revenue $209.4M (+4.2% y/y, +10.3% q/q)
  • Full-year 2025 revenue $4.0B (+1% y/y); Clear aligner $3.2B (+0.5% y/y) on 2.6M cases (+4.7% y/y); Systems & Services $790M (+2.7% y/y)
  • Full-year teens/kids starts 936k (+7.8% y/y); Q4 teens/growing kids starts 230k (+7% y/y; -9.8% q/q after strong Q3 season)
  • Regional strength y/y in EMEA, Latin America, and APAC; stability in North America; Latin America delivered record shipments

Business Development

  • Deepened DSO/OSO partnerships across regions; top 10 DSOs in the Americas grew double digits y/y with double-digit retention
  • Surpassed 1M Invisalign patients treated in Latin America; also exceeded 1M in the UK and in Iberia
  • HFD patient financing partnership expanding, supporting incremental Invisalign treatments
  • iTero Lumina represented ~86% of full-system units in Q4; continued installations driving utilization
  • Exocad ART (Advanced Restorative Treatment) piloted in several European markets with broader rollout planned in 2026
  • Limited market release in 2026 of 3D-printed Invisalign First retainers and Invisalign Specifics prefab attachments; more complex 3D-printed products targeted for 2027
  • Invisalign Specific Attachment System used in 1,000+ patients with positive clinical feedback

Financials

  • Q4 GAAP gross margin 65.3% (+1.1 pts q/q; -4.8 pts y/y); non-GAAP gross margin 72.0% (+1.6 pts q/q; +1.2 pts y/y)
  • Full-year 2025 non-GAAP operating margin 22.7% (above outlook); Q4 non-GAAP operating margin highest since 2021
  • Q4 clear aligner ASP $1,240 (-$5 q/q; -$25 y/y) driven by higher discounts and mix; price increases partly offset y/y decline
  • Clear aligner deferred revenue decreased $33.9M q/q (-2.9%) and $61.4M y/y (-5.1%)
  • Systems & Services deferred revenue flat q/q; decreased $24.6M y/y (-11.2%) due to shorter initial service contract durations
  • FX impact on revenue: -$3.0M q/q (~-0.3%); +$14.8M y/y (~+1.4%); FX impact on GM: -0.1 pts q/q; +0.5 pts y/y
  • Q4 clear aligner GM 64.2% (-0.7 pts q/q; -6.0 pts y/y); Systems & Services GM 69.6% (+8.4 pts q/q; +0.2 pts y/y)
  • Q4 doctors submitting Invisalign cases: 88,000 (record for a Q4)

Capital & Funding

  • No capital markets or liquidity updates disclosed in the provided remarks

Operations & Strategy

  • DSOs/OSOs emphasized as scalable, digitally driven growth channel accelerating Invisalign and iTero adoption
  • Practice playbook: scan every patient, use chairside visualization, localized marketing, and offer third-party patient financing to improve conversion
  • Portfolio flexibility with lower upfront cost options and streamlined configurations (e.g., no additional aligners) to broaden access while maintaining margins
  • Transitioning from thermoforming to direct 3D printing to enhance design flexibility, reduce waste, and lower costs over time (near-term margin dilution until scaled)
  • Building an integrated digital platform across diagnostics (AXI, Oral Health Suite), restorative (Exocad), and orthodontics (Invisalign) to increase relevance with GPs and labs
  • Local manufacturing, regulatory, and commercial infrastructure in China to navigate VPP and support market-specific portfolio

Market & Outlook

  • China Volume-based Procurement (VPP) implementation delayed; expected to start in public hospitals first; >85% of China business is private sector; Align believes it is well positioned
  • DSO momentum expected to continue as consolidation drives digital workflows and efficiency
  • Exocad ART broader rollout planned in 2026 to deepen restorative and lab integration
  • Limited market release of select 3D-printed products in 2026; broader portfolio to follow in 2027
  • North American consumer sentiment and patient inflows remain pressured in retail practices despite improving utilization

Risks Or Headwinds

  • Softness in North American retail orthodontic market and pressured consumer demand
  • Potential pricing pressure from China VPP once implemented
  • Higher discounts and mix shift to lower-priced countries/products weighing on ASP
  • Foreign exchange volatility affecting revenue and margins
  • Early-stage direct 3D fabrication is margin dilutive until scale is achieved
  • Declines in deferred revenue may temper future revenue recognition
  • Lower scanner wand sales and lower ASPs in Systems & Services

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ALGN Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ALGN)

© 2026 Stock Market Info — Align Technology, Inc. (ALGN) Financial Profile